Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials - Scorecard - MDSpire

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

  • By

  • Jerry Bagel

  • Ranga Gogineni

  • Asif Shaikh

  • Mark G. Lebwohl

  • March 16, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

At a Glance

CategoryDetail
Condition
Key MechanismsTildrakizumab is an IL-23 monoclonal antibody targeting inflammatory pathways associated with psoriasis and diabetes, potentially reducing systemic inflammation.
Target Population
Care Setting

Key Highlights

  • Specify that higher rates of PASI 75 and PGA 0/1 responses were observed in tildrakizumab-treated patients compared to placebo.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • m
      • e
      • t
      • a
      • b
      • o
      • l
      • i
      • c
      • p
      • a
      • r
      • a
      • m
      • e
      • t
      • e
      • r
      • s
      • s
      • u
      • c
      • h
      • a
      • s
      • H
      • b
      • A
      • 1
      • c
      • ,
      • f
      • a
      • s
      • t
      • i
      • n
      • g
      • g
      • l
      • u
      • c
      • o
      • s
      • e
      • ,
      • a
      • n
      • d
      • l
      • i
      • p
      • i
      • d
      • p
      • r
      • o
      • f
      • i
      • l
      • e
      • s
      • .

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • evaluation

        References

        Original Source(s)

        Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

        • by Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl

        • March 16, 2026

        Related Content

        Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial

        Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

        Biologics Tied to Lower Eye Risk in Psoriasis

        Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.